In 2016, Ali Health experienced two major crises in which the drug monitoring code was stopped and the third-party retail of drugs was stopped. Ali’s main business was hit hard. Since then, Ali Health has successively carried out business supplements and transformations in the new retail of medical health. On May 21, Ali Health announced that the company's affiliated Hongyun Jiukang Data Technology (Beijing) Co., Ltd. (hereinafter referred to as Hongyun Jiukang) intends to inject Jiahe Meikang (Beijing) Technology Co., Ltd. (hereinafter referred to as Jiahe Meikang) Cash was about 291 million yuan, of which 150.459 million yuan was used to increase registered capital, and about 276 million yuan was used as capital reserve. After the capital increase is delivered, its existing shareholders and Hongyun Jiukang hold 85% and 15% respectively.
On the same day, Hongyun Jiukang also injected 40 million yuan in cash into Beijing Jiamei Online Technology Co., Ltd. (hereinafter referred to as Jiamei Online), of which 36.654 million yuan was used to increase the registered capital and 3,345,500 yuan was used as the capital reserve. After the capital increase, the existing shareholders and Hongyun Jiukang hold 55% and 45% respectively.
The announcement shows that Jiahe Meikang is an investment holding company and its operating subsidiaries (including Jiamei Online) are mainly engaged in research, development, production, sales and provision of clinical information software products and infant medical equipment . These products include electronic medical record services, hospital data integration platforms and infant ventilators.
As of December 31, 2016, during the two annual periods, Jiahe Meikang's net profit after tax and non-recurring items was RMB 26.092 million and RMB 23.821 million, respectively.
↑阿里å¥åº·å®˜ç½‘Home
Ali Health said that the proposed capital increase is an opportunity to promote business cooperation between the Group, the Target Group and the Target Subsidiaries. This strategic cooperation will help the Group integrate its additional medical service resources and promote its mission for its Internet-level medical service network. Bring a more diversified source of income.
In addition, Ali Health also spent 3.8 billion yuan to integrate the health care products on the Alibaba Tmall platform three days ago. On May 19th, Ali Health announced that it officially signed a share subscription agreement with Alibaba Group. Alibaba Group injected the 3.8 billion Hong Kong dollar Tmall platform “Blue Hat†health food online business into Ali Health. Upon completion of the transaction, Alibaba Group's shareholding in Ali Health will increase from approximately 37.9% to approximately 45.8%, and voting rights will increase from approximately 54% to approximately 59.8%.
“Blue Hat†is a health food mark approved by the State Food and Drug Administration and is generally regarded as a general term for health food. Health food has a high profit margin, rapid growth and great potential in the medical field, but the market layout and product quality are more chaotic.
According to the announcement, as of the fiscal year ended March 31, 2017, more than 950 merchants selling health food on Tmall's pharmaceutical platform will be injected into Ali Health, an active health food buyer on Tmall's pharmaceutical platform in the past year. More than 11.81 million, the blue hat health food business turnover was about 2.772 billion yuan.
After the transaction is completed, Ali Health will obtain the business contract relationship of the “Blue Hat†health food merchants on the Tmall Medicine platform, providing a series of value-added services including stationing, brand marketing and technical support, and receiving commissions. Ali Financial News shows that in the 2017 fiscal year, the health care products business brought a commission income of 62.27 million yuan to the Tmall platform.
Ali Health believes that the acquisition target business can integrate a wider range of e-commerce businesses into the medical and healthcare online community to enrich the ecology, and complement the company's pharmaceutical e-commerce business, smart medical services, product traceability platform services. On the other hand, it is possible to obtain more stable sustainable income growth.
Curcumin powder,Curcumin 95%,Turmeric root Extract.
Shaanxi Zhongyi Kangjian Biotechnology Co.,Ltd , https://www.zyplantextract.com